Building on their work with HER2/IL13Ra TanCAR and in an attempt to address the limitations mentioned, Bielamowicz et al. designed trivalent CAR T with the addition of EphA2 and the intent to capture 95% or more of the tumor population. This evidence concerns the gene EPHA2 and neoplasm.